CONTACT US
Press

egnite Chosen as Finalist for Octane’s 2021 High Tech Awards

Octane’s annual High Tech Awards celebrates and recognizes individuals and companies who make Orange County a center of medical technology innovation. Throughout 28 years, the High Tech Awards have recognized more than 150 innovative companies. The annual event consists of 10 different categories ranging from Outstanding Small Technology Company to Best Technology Company Leadership Team and Best Small Technology CEO.

Octane announced the finalists for their 2021 High Tech Awards. egnite was chosen as a finalists for the “Outstanding Innovation in Medical Technology/Life Sciences” category at the 2021 High Tech Awards. This award is specifically for the innovation of a medtech/life science device or product. egnite’s CardioCare platform was nominated as the first to market solution leveraging artificial intelligence and predictive algorithms to identify the most at-risk structural heart patients to help physicians ensure patients don’t fall through the cracks.

CardioCare is making a difference by partnering with over 50 heart programs to help manage hospital’s vast structural heart patient populations and elevate the standard of patients care. Within one year of using the CardioCare platform, hospitals have observed a 29% improvement in patients diagnosed and a 35% increase in patients referred to a cardiovascular specialist.*

“We are using vast amounts of data to solve big problems and close gaps in patient care,” said Joel Portice, chief executive officer, egnite. “We believe this is the first of many AI applications that will become a game changer for our physician partners and deliver meaningful improvements in patient care, with the potential to save thousands of lives. Now, more than ever we are acting with urgency to get these AI solutions into providers’ hands.”

To learn more about CardioCare’s predictive suite, click here. 

*Analysis represents aggregate median performance across 14 sites with baseline data after six months of using the CardioCare program.

#DigitalHealth #PrecisionMedicine #ArtificialIntelligenceSolutions

Linkedin-in Twitter Youtube

Related Articles
egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,
egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

© 2025 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.

Privacy Policy    Intellectual Property    Terms of Use    Implementation Kit    Careers

Linkedin Twitter
Linkedin Twitter

© 2021 egnite, Inc. All Rights Reserved.  egnite, egnite Inc., and the stylized logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.

CONTACT US